Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sotalol Hydrochloride

FDA-approved product (tablet, oral), marketed as Betapace, Betapace Af, Sorine and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Sotalol Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Ventricular arrhythmia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Beta blocking agents, non-selective
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA22.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sotalol Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sotalol Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Optimal Pharmacological Therapy In Implantable Defibrillator Patients (OPTIC)

    NCT00257959 · start 2001-01

    Registered record
    Registry ID
    NCT00257959
    Conditions
    Ventricular Tachycardia
    Interventions
    amiodarone beta blocker sotalol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-01
    Completion
    2004-10
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentricular Tachycardia
    Interventionamiodarone beta blocker sotalol
    PhasePhase 4
    Registry statusCompleted

  • Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm

    NCT00007605 · start 1998-04

    Registered record
    Registry ID
    NCT00007605
    Conditions
    Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden
    Interventions
    Amiodarone; Sotalol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-04
    Completion
    2003-12
    Enrolment
    706

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation; Cerebrovascular Accident; Death, Sudden
    InterventionAmiodarone; Sotalol
    PhasePhase 3
    Registry statusCompleted

  • Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)

    NCT00000556 · start 1995-03

    Registered record
    Registry ID
    NCT00000556
    Conditions
    Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
    Interventions
    amiodarone; sotalol; propafenone; flecainide; quinidine; moricizine; disopyramide; procainamide; adrenergic beta antagonists; verapamil; diltiazem; digoxin; catheter ablation; pacemaker, artificial
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-03
    Completion
    2002-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases
    Interventionamiodarone; sotalol; propafenone; flecainide +10 more
    PhasePhase 3
    Registry statusCompleted

  • Antiarrhythmics Versus Implantable Defibrillators (AVID)

    NCT00000531 · start 1992-09

    Registered record
    Registry ID
    NCT00000531
    Conditions
    Arrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases; Tachycardia, Ventricular; Ventricular Fibrillation
    Interventions
    defibrillators, implantable; amiodarone amiodarone; sotalol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1992-09
    Completion
    2002-08
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases +2 more
    Interventiondefibrillators, implantable; amiodarone amiodarone; sotalol
    PhasePhase 3
    Registry statusCompleted

  • Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)

    NCT00000518 · start 1985-07

    Registered record
    Registry ID
    NCT00000518
    Conditions
    Arrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases; Tachycardia, Ventricular; Ventricular Arrhythmia; Ventricular Fibrillation
    Interventions
    electrophysiology; electrocardiography, ambulatory; imipramine; mexiletine; procainamide; quinidine; sotalol
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1985-07
    Completion
    1992-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArrhythmia; Cardiovascular Diseases; Death, Sudden, Cardiac; Heart Diseases +3 more
    Interventionelectrophysiology; electrocardiography, ambulatory; imipramine; mexiletine +3 more
    PhasePhase 3
    Registry statusCompleted